Compounded Semaglutide vs Wegovy: 2026 Monthly Cost Head-to-Head

Last reviewed: September 18, 2026 Last updated: September 18, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

PlexusDx publishes this comparison and is one of the providers discussed. We use the same evidence rules for our own program and competing programs.

The short answer

Compounded semaglutide injection costs $149–$299 per month all-inclusive on month-to-month plans across the telehealth market (PlexusDx $189/month month-to-month, OrderlyMeds $149/month standard refill, Henry Meds $297/month, Embody $299/month). Wegovy—the FDA-approved brand-name semaglutide—splits into two routes: oral pill programs run $223–$349/month including mandatory membership (WeightWatchers Clinic $223/month after promotional period, Ro $298/month, Rex MD $349/month all-in), while Wegovy pen injection costs $1,549–$1,839 per 28-day supply (Levity $1,599/month ongoing, OrderlyMeds $1,839/month). The core trade-off: compounded semaglutide is not FDA-approved and is produced by 503A pharmacies under state boards of pharmacy, while Wegovy carries full FDA approval for chronic weight management. Cost advantage depends on route—compounded injection undercuts Wegovy pill by $34–$160/month and Wegovy pen by over $1,250/month, but Wegovy pill remains the only oral FDA-approved semaglutide available through these channels.

At-a-glance: Compounded semaglutide vs Wegovy monthly cost

Source: provider websites captured September 4–18, 2026. Wegovy pill figures reflect starting dose (1.5 mg); higher doses cost more. MEDVi first-month introductory rate is $179; the $299 figure shown is the standard refill rate. OrderlyMeds compounded figure is standard refill; 2-month starter pack runs $74.50/month ($149 total upfront). WeightWatchers Clinic membership reflects standard rate after 2-month promotional period at $25/month.

Normalized 12-month cost: compounded semaglutide injection vs Wegovy pill vs Wegovy pen

Month-to-month headline rates obscure prepayment requirements, first-month promotions, membership splits, and dose escalation. Below we calculate total 12-month cost for a patient starting at introductory dose and remaining on starting or maintenance dose (Wegovy pill 1.5 mg, compounded semaglutide injection typical provider flat-dose policy, Wegovy pen representative 28-day supply).

Compounded semaglutide injection (month-to-month, flat dose across titration)

• PlexusDx: $189/month × 12 = $2,268 (our calculation)
• OrderlyMeds: 2-month starter $149 ($74.50/month prepaid upfront = $149 total) + 10 months × $149 refill = $149 + $1,490 = $1,639 (our calculation)
• Henry Meds: $297/month × 12 = $3,564 (our calculation)
• MEDVi: $179 first-month introductory rate + $299 standard refill × 11 = $179 + $3,289 = $3,468 (our calculation)
• Embody: $299/month × 12 = $3,588 (our calculation)

Wegovy pill (month-to-month, starting dose 1.5 mg)

• WeightWatchers Clinic: Month 1–2 promotional membership $25/month + $149 Wegovy = $174/month × 2 = $348; Month 3–12 standard membership $74/month + $149 Wegovy = $223/month × 10 = $2,230; Total = $348 + $2,230 = $2,578 (our calculation, assuming 12-month commitment and starting dose throughout)
• Ro: Medication $149/month + Body Program membership $149/month = $298/month × 12 = $3,576 (our calculation, month-to-month membership)
• LifeMD: Wegovy pill $149/month + membership $39 first-month promotional rate then $149/month = ($149 + $39) + ($149 + $149) × 11 = $188 + $3,278 = $3,466 (our calculation)
• Rex MD: $349/month all-inclusive × 12 = $4,188 (our calculation)

Wegovy pen (month-to-month, ~28-day supply)

• Levity: First refill $1,549 + 11 months × $1,599 = $1,549 + $17,589 = $19,138 (our calculation, assuming ~13 fills over 12 months at 28-day intervals; conservative 12-fill estimate = $1,549 + $1,599 × 11 = $19,138)
• OrderlyMeds: $1,839/month × 12 = $22,068 (our calculation, assuming monthly supply)

All 12-month totals are our calculation from the provider's published rates and terms. WeightWatchers Clinic figure assumes continuous starting dose and includes the 2-month promotional membership period. Dose escalation, higher maintenance doses, or mid-year plan changes will alter totals. Wegovy pen figures assume ~monthly fills; actual refill intervals may differ.

FDA approval status: the central regulatory divide

Wegovy is FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, and in pediatric patients aged 12 years and older with obesity. The FDA reviewed clinical trial data—including the STEP trial program—for safety, efficacy, manufacturing quality, and labeling before granting approval. Wegovy is manufactured by Novo Nordisk under current Good Manufacturing Practice (cGMP) standards and carries FDA-mandated prescribing information, black-box warnings (thyroid C-cell tumors in rodents), and post-market surveillance.

Compounded semaglutide is not FDA-approved. Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient. Compounding pharmacies operate under state boards of pharmacy; 503A facilities compound patient-specific prescriptions and are not subject to the same pre-market review, cGMP enforcement, or batch testing as FDA-approved manufacturers. The active pharmaceutical ingredient (semaglutide peptide) is the same, but formulation, excipients, sterility assurance, and supply-chain oversight differ. Compounded semaglutide is not interchangeable with Wegovy.

This regulatory difference underpins the cost gap: Wegovy's price reflects branded drug development, FDA approval costs, and manufacturer distribution; compounded semaglutide pricing reflects per-prescription pharmacy compounding and telehealth service margins.

Route and formulation: injection vs oral pill

Compounded semaglutide in the telehealth market is available almost exclusively as subcutaneous injection, supplied in pre-filled syringes or vials with insulin syringes for weekly self-administration. Wegovy is available in two routes:

• Wegovy pen (injection): FDA-approved pre-filled, single-dose pen injector for subcutaneous injection, identical active ingredient and route to compounded injection, supplied in escalating dose strengths (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg weekly).
• Wegovy pill (oral): FDA-approved oral semaglutide tablet, taken daily, requiring specific administration instructions (empty stomach, 30 minutes before food/drink/other medications). The pill formulation uses absorption enhancers (SNAC, sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) to enable gastrointestinal uptake of the peptide.

Injection and oral routes are not clinically interchangeable—dosing schedules, titration protocols, and pharmacokinetic profiles differ. Patients who prefer to avoid needles may favor the oral pill despite higher cost; patients comfortable with weekly injection may prioritize cost and choose compounded injection. The oral Wegovy pill carries the FDA-approval advantage; compounded oral semaglutide exists in limited telehealth channels (MEDVi offers compounded tablet at +$70/month over injection) but remains non-FDA-approved.

Dose policy and cost predictability across titration

Semaglutide therapy follows a multi-week titration schedule, starting at low dose (typically 0.25 mg weekly injection or related oral dose) and escalating to maintenance dose (commonly 1 mg, 1.7 mg, or 2.4 mg weekly injection) over 16–20 weeks to minimize gastrointestinal side effects. Pricing models handle titration differently:

Compounded semaglutide: predominantly flat-dose pricing

Most compounded providers charge the same monthly rate regardless of dose throughout titration and maintenance (PlexusDx $189/month every dose, Embody $299/month every dose, Henry Meds $297/month every dose). OrderlyMeds and MEDVi maintain flat refill rates after introductory pricing ($149/month and $299/month respectively). This yields cost predictability—patients pay the same amount whether on starting dose or maintenance dose.

Wegovy pill: dose-dependent pricing

Wegovy pill programs separate starting dose (1.5 mg) from higher dose (25 mg). Ro, WeightWatchers Clinic, and LifeMD advertise $149/month for 1.5 mg starting dose; higher-dose prescriptions cost $299/month medication fee (LifeMD 25 mg confirmed, Ro and WeightWatchers Clinic dosing inferred from parallel program architectures). Membership fees remain constant. A patient titrating from 1.5 mg to 25 mg sees medication cost double mid-program, raising total monthly outlay from $223–298 to $373–448 depending on provider.

Wegovy pen: dose strength included in pen price

Wegovy pen pricing at Levity and OrderlyMeds reflects full pen supply; dose escalation is managed by pen strength selection rather than separate dose fees. The $1,599–1,839/month figure applies across the dose range, but wholesale acquisition cost and insurance reimbursement structures price higher-dose pens higher in traditional channels—cash telehealth channels appear to average across doses or price at maintenance dose.

Bottom line: compounded semaglutide flat-dose pricing eliminates mid-program cost surprises during titration; Wegovy pill dose-dependent pricing raises monthly cost when stepping up to maintenance dose; Wegovy pen pricing is uniformly high across doses.

Membership fees and billing structure

Compounded semaglutide providers in this comparison charge no separate membership fee—PlexusDx, OrderlyMeds, Henry Meds, MEDVi, Embody, and others bundle clinician access, messaging support, and care coordination into the single monthly medication fee. The patient pays one price, receives medication and clinical support, and may cancel month-to-month (prepaid plans exist but do not introduce recurring membership).

Wegovy pill programs at Ro, LifeMD, and WeightWatchers Clinic split medication cost from membership cost. Ro's Body Program membership is $149/month (month-to-month), $89/month on 6-month prepaid ($534 upfront), or $74/month on annual prepaid ($888 upfront). LifeMD membership is $39 first-month promotional rate, then $149/month ongoing. WeightWatchers Clinic membership is $25/month promotional rate for the first two months on a 12-month commitment, then $74/month for months 3–12. Rex MD bundles medication and program into a single $349/month fee with no separate membership. Wegovy pen programs (Levity, OrderlyMeds pen pathway) advertise no separate membership.

The membership split introduces budget complexity: a patient comparing $149/month Wegovy pill at Ro to $189/month compounded semaglutide at PlexusDx must add Ro's $149/month membership to reach the true $298/month total—$109/month more than PlexusDx's all-inclusive rate.

Prepaid discounts and monthly cost reduction

Both compounded and Wegovy pill providers offer prepaid plans that lower effective monthly cost in exchange for upfront payment:

Compounded semaglutide prepaid examples

• PlexusDx: $189/month month-to-month, $169/month on 3-month prepaid ($507 upfront), $149/month on 6-month prepaid ($894 upfront)—a $40/month reduction from month-to-month on the 6-month plan.
• Henry Meds: $297/month month-to-month, $297/month on 6-month prepaid ($1,782 upfront), or $197/month on 12-month paid-in-full ($2,364 upfront)—a $100/month reduction on the annual paid-in-full plan.
• Found: $289/month month-to-month cash-pay, or $169/month effective on annual prepaid ($2,028 upfront)—a $120/month reduction.

Wegovy pill membership prepaid examples

• Ro Body Program: $149/month membership month-to-month, $89/month on 6-month prepaid ($534 upfront), $74/month on annual prepaid ($888 upfront)—a $75/month membership reduction on the annual plan, bringing total monthly cost (membership + $149 starting-dose Wegovy pill) from $298 to $223.
• WeightWatchers Clinic: $25/month membership promotional rate months 1–2, $74/month months 3–12 on 12-month commitment—no month-to-month membership option disclosed; 12-month commitment is baseline.

Prepaid plans reduce per-month cost but require upfront capital and limit flexibility to switch providers, pause treatment, or stop without forfeiting prepaid months. Month-to-month plans cost more per month but preserve the option to cancel at any billing cycle. Patients uncertain about tolerance, response, or insurance changes over the next 6–12 months may prefer month-to-month; patients confident in their choice and able to prepay benefit from the discount.

Insurance, copay assistance, and manufacturer coupons

Wegovy—being FDA-approved—is eligible for insurance coverage under many commercial plans (coverage varies by plan and requires prior authorization in most cases) and for Novo Nordisk copay savings programs where applicable. Patients with insurance covering Wegovy may pay significantly less than the cash prices cited here (Found advertises ~$30 typical copay on its insurance-support track, for example). Compounded semaglutide is not FDA-approved, not covered by insurance, and not eligible for manufacturer copay cards—patients pay the full telehealth cash price.

For patients with insurance covering Wegovy and willing to navigate prior authorization, the effective cost may be far lower than any cash compounded option. For patients without insurance coverage, in plans excluding GLP-1s for weight loss, or unwilling to complete prior-auth processes, the cash prices compared here apply, and compounded semaglutide's cost advantage is significant.

Why does Wegovy pen cost 5–12× compounded semaglutide?

Wegovy pen cash pricing ($1,549–1,839/month) reflects Novo Nordisk's list price for the FDA-approved, branded, pre-filled pen device, channeled through traditional pharmacy distribution or manufacturer cash-pay programs (Levity and OrderlyMeds both appear to source Wegovy pen through these pathways). This price is designed for insurance reimbursement, not cash-pay; the majority of Wegovy pen prescriptions are paid by insurance or via manufacturer copay programs, leaving the uninsured or coverage-denied patient exposed to the full list price. Compounded semaglutide, produced by 503A pharmacies on a per-prescription basis without FDA approval costs or branded distribution markups, prices far lower. The Wegovy pen offers FDA-approved quality assurance, pen-injector convenience, and the backing of full clinical trial data; compounded injection offers the same active peptide at a fraction of the cost but without FDA review or branded device form factor.

Choose compounded semaglutide injection if…

• You pay cash (no insurance coverage or coverage excludes GLP-1s for weight loss), making Wegovy pen's $1,549–1,839/month and Wegovy pill's $223–349/month (with membership) prohibitive.
• You are comfortable with weekly self-injection using a syringe or auto-injector pen (compounded providers supply pre-filled syringes or vials with needles).
• You accept that compounded semaglutide is not FDA-approved and that FDA does not review compounded drugs for safety, effectiveness, or quality before marketing.
• You prioritize flat-dose pricing predictability—knowing your monthly cost will not double when titrating from starting to maintenance dose.
• You want month-to-month flexibility with no membership fees, allowing you to pause or cancel without forfeiting prepaid months or ongoing membership charges.
• You want the lowest 12-month cost: OrderlyMeds compounded at $1,639 total year one, PlexusDx at $2,268, versus WeightWatchers Clinic Wegovy pill at $2,578 minimum (and Wegovy pen over $19,000).

Choose Wegovy pill if…

• You want FDA-approved medication backed by the STEP clinical trial program and Novo Nordisk's manufacturing quality standards.
• You strongly prefer oral administration over injection and are willing to follow the required daily oral dosing protocol (empty stomach, 30-minute wait before food/drink).
• You have insurance covering Wegovy or qualify for Novo Nordisk copay savings, bringing your effective cost below $150–200/month total.
• You accept dose-dependent pricing (starting dose $149/month medication, higher dose $299/month) plus membership fees ($74–149/month depending on provider and prepay commitment).
• You value integrated coaching and behavioral-support programs bundled into the membership (WeightWatchers Clinic behavioral coaching, Ro Body Program content) and are willing to pay the membership fee for those services.
• The total monthly outlay of $223–349 (after any promotional periods) fits your budget, and the FDA-approval peace-of-mind justifies the premium over compounded options.

Choose Wegovy pen if…

• You have insurance covering Wegovy pen with manageable copay, or you qualify for manufacturer patient-assistance programs that lower the $1,549–1,839/month cash price significantly.
• You want FDA-approved semaglutide injection in the branded single-dose pen device (easier pen-injector mechanism, dose-dial interface, pharmaceutical packaging).
• You are willing to pay the substantial cash premium ($1,300–1,650/month over compounded injection, $1,250–1,516/month over Wegovy pill programs) for the branded pen form factor and FDA approval.
• Cost is not a primary constraint, and you prioritize the regulatory and device advantages of the branded pen over telehealth compounded or pill alternatives.

Where PlexusDx compounded semaglutide injection fits

PlexusDx compounded semaglutide injection is $189/month month-to-month, $169/month on 3-month prepaid, $149/month on 6-month prepaid—middle of the compounded injection market, below Henry Meds ($297), Embody ($299), and MEDVi refill ($299), above OrderlyMeds refill ($149), in line with other mid-tier compounded providers. PlexusDx uses flat-dose pricing (same $189/month whether on 0.25 mg starting dose or 2.4 mg maintenance dose), no membership fee, and month-to-month cancel-anytime terms on the base plan. The 6-month prepaid plan ($894 upfront, $149/month effective) matches OrderlyMeds' ongoing refill rate and undercuts all other compounded month-to-month options except OrderlyMeds' starter.

PlexusDx works with licensed 503A compounding pharmacies. Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient.

Choose PlexusDx compounded semaglutide injection if you want predictable flat-dose pricing, no separate membership, mid-market monthly cost with the option to drop to $149/month via 6-month prepay, and month-to-month flexibility. PlexusDx costs $34–160/month less than Wegovy pill programs (depending on provider and membership plan) and $1,360–1,650/month less than Wegovy pen, but carries no FDA approval. For patients paying cash and comfortable with compounded medication, PlexusDx offers a cost-effective, transparent semaglutide injection pathway.

Methodology and freshness

Pricing, terms, and inclusions were captured from provider websites, checkout flows, and FAQ pages between July 23 and September 18, 2026. Wegovy pill figures reflect starting-dose medication cost (1.5 mg) plus membership where applicable; higher-dose (25 mg) costs $299/month medication at LifeMD (confirmed at checkout) and are inferred to follow similar structure at Ro and WeightWatchers Clinic based on parallel program architectures. Wegovy pen figures are published all-inclusive rates at Levity and OrderlyMeds. Compounded semaglutide figures are published month-to-month and prepaid rates from provider primary pages and pricing pages. All 12-month cost calculations are our calculation, derived by multiplying or summing the provider's published rates and labeled as such. We used each provider's most transparent rate; where promotional first-month or starter-pack pricing appeared, we separated it from ongoing refill rates and calculated 12-month cost accordingly (OrderlyMeds 2-month starter $149 total, then $149/month refill; MEDVi first-month introductory rate $179, standard refill $299; WeightWatchers Clinic promotional membership rate $25/month months 1–2, $74/month months 3–12). Where evidence was ambiguous or checkout gates prevented full rate confirmation, we noted the limitation. PlexusDx pricing is from the live product page and pricing documentation captured September 18, 2026. No promotional codes, discount arithmetic, or unapproved figures were used. Readers should confirm current rates, dose-specific costs, and insurance coverage at checkout before committing.

Frequently Asked Questions

Is compounded semaglutide interchangeable with Wegovy?

No. Compounded semaglutide and Wegovy both contain the semaglutide peptide, but compounded semaglutide is not FDA-approved, not manufactured under FDA cGMP standards, and not interchangeable with Wegovy. Wegovy is FDA-approved for chronic weight management and produced by Novo Nordisk with full regulatory review. Compounded semaglutide is produced by state-licensed 503A pharmacies on a per-prescription basis without FDA pre-market review.

Why does Wegovy pill cost more than compounded semaglutide injection?

Wegovy pill programs ($223–349/month) include both FDA-approved oral semaglutide medication and mandatory membership fees for clinical programs, coaching, and support. Compounded semaglutide injection ($149–299/month) is not FDA-approved, has no separate membership fee, and reflects compounding-pharmacy production costs rather than branded pharmaceutical pricing. The oral route and FDA approval add cost; the membership split raises the total monthly outlay above medication alone.

Can I use insurance or manufacturer coupons for compounded semaglutide?

No. Compounded medications are not FDA-approved and are not covered by insurance. Novo Nordisk manufacturer copay cards and patient-assistance programs apply only to FDA-approved Wegovy and Ozempic, not to compounded semaglutide. Patients using compounded semaglutide pay the full cash price. Patients with insurance covering Wegovy may pay far less via insurance reimbursement and copay assistance than the cash prices compared here.

Does the monthly price change when I increase my semaglutide dose?

It depends on the provider and product. Most compounded semaglutide providers (PlexusDx, Henry Meds, Embody, OrderlyMeds, MEDVi) use flat-dose pricing—you pay the same monthly rate whether on starting dose (0.25 mg weekly) or maintenance dose (1 mg, 1.7 mg, 2.4 mg). Wegovy pill programs charge $149/month medication for starting dose (1.5 mg) and $299/month medication for higher dose (25 mg), plus ongoing membership fees, so your total monthly cost rises when stepping up. Wegovy pen pricing averages across doses at the high end ($1,549–1,839/month).

Which is safer: compounded semaglutide or Wegovy?

Wegovy is FDA-approved, meaning the FDA reviewed clinical trial data for safety and efficacy, mandates specific manufacturing standards (cGMP), and requires post-market surveillance and adverse-event reporting. Compounded semaglutide is not FDA-approved; FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. State boards of pharmacy oversee 503A compounding pharmacies, but standards and enforcement differ from FDA pharmaceutical manufacturing oversight. Both products carry the same GLP-1 receptor agonist side-effect profile (nausea, vomiting, diarrhea, rare pancreatitis, thyroid C-cell tumor risk in rodents); the difference is regulatory oversight and quality assurance, not the peptide's pharmacology.

Sources

• PlexusDx compounded semaglutide injection pricing and terms, https://plexusdx.com/pages/glp-1-alternatives, accessed September 18, 2026.
• Ro Wegovy pill pricing and Body Program membership, https://ro.co/weight-loss/pricing/ and https://ro.co/weight-loss/wegovy-pill-cost/, accessed September 4, 2026.
• WeightWatchers Clinic Wegovy pill and membership pricing, https://www.weightwatchers.com/us/weight-loss-medication and https://www.weightwatchers.com/us/weight-loss-medication/wegovy-pill, accessed September 4, 2026.
• LifeMD Wegovy pill and membership pricing, https://lifemd.com/weight-management and https://lifemd.com/weight-management/wegovy-pill-25mg/, accessed September 4, 2026.
• OrderlyMeds Wegovy pen and compounded semaglutide pricing, https://orderlymeds.com/pricing/, accessed September 4, 2026.
• Levity Wegovy pen pricing, https://www.joinlevity.com/, accessed September 4, 2026.
• Rex MD Wegovy pill program pricing, https://rexmd.com/weight-management/, accessed September 4, 2026.
• Henry Meds compounded semaglutide injection pricing, https://henrymeds.com/legal/programs, accessed September 4, 2026.
• MEDVi compounded semaglutide injection and refill pricing, https://glp1.medvi.org/, checkout-verified, accessed September 4, 2026.
• Found compounded semaglutide pricing, https://joinfound.com/plans-and-pricing, accessed September 4, 2026.
• Eden, Embody, Peak Wellness, TrimRx, Mochi Health, Fridays Health, Remedy Meds, Willow compounded semaglutide pricing, various provider websites, accessed July 23 – September 4, 2026.

Compounded medication disclosure: Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient. PlexusDx works with licensed 503A compounding pharmacies.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.